Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
- Condition Stage III Lung Non-Small Cell Cancer AJCC v7
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Carcinoma, Non-Small-Cell Lung
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
- Trial name
- NCT04529564
- Where
- 12 sites in Taiwan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Lung Cancer
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary…
- Trial name
- REVEAL (NCT04836975)
- Where
- Saudi Arabia
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer (NSCLC)
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
This large multinational, non-interventional study (NIS), will retrospectively collect data derived from established medical records over a period of up to approximately 6 years (2013 to 2018), building a platform to capture and…
- Trial name
- KINDLE (NCT03725475)
- Where
- 32 sites in Argentina, Chile and 8 more
- Volunteers
- 3,111 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC
This observational study is designed to assess the long term safety of the durvalumab treatment period including subsequent treatment period and demonstrate the efficacy of patients treated with durvalumab following…
- Trial name
- AYAME (NCT03995875)
- Where
- 43 sites in Japan
- Volunteers
- 529 people
- Sponsor
- AstraZeneca